China SXT Pharmaceuticals Inc (NASDAQ: SXTC)’s stock price has gone decline by -4.58 in comparison to its previous close of 1.31, however, the company has experienced a -14.38% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-03-17 that TAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) — China SXT Pharmaceuticals, Inc. (Nasdaq: SXTC) (the “Company”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced that the Company received a written notification (the “Compliance Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated March 13, 2025, informing the Company that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”) and the matter is closed.
Is It Worth Investing in China SXT Pharmaceuticals Inc (NASDAQ: SXTC) Right Now?
The price-to-earnings ratio for China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is 0.06x, which is above its average ratio. Moreover, the 36-month beta value for SXTC is 1.10.
The public float for SXTC is 25.96M and currently, short sellers hold a 0.36% of that float. On June 05, 2025, SXTC’s average trading volume was 4.12M shares.
SXTC’s Market Performance
SXTC stock saw a decrease of -14.38% in the past week, with a monthly decline of -39.02% and a quarterly a decrease of -77.44%. The volatility ratio for the week is 2.85%, and the volatility levels for the last 30 days are 10.58% for China SXT Pharmaceuticals Inc (SXTC). The simple moving average for the last 20 days is -20.74% for SXTC’s stock, with a simple moving average of -65.00% for the last 200 days.
SXTC Trading at -36.39% from the 50-Day Moving Average
After a stumble in the market that brought SXTC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.51% of loss for the given period.
#####
#####
Stock Fundamentals for SXTC
Current profitability levels for the company are sitting at:
- 6.91 for the present operating margin
- 0.27 for the gross margin
The net margin for China SXT Pharmaceuticals Inc stands at 6.67. The total capital return value is set at 0.48. Equity return is now at value 57.63, with 25.43 for asset returns.
Based on China SXT Pharmaceuticals Inc (SXTC), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -0.51.
Currently, EBITDA for the company is -2.35 million with net debt to EBITDA at -1.28. When we switch over and look at the enterprise to sales, we see a ratio of 24.56. The receivables turnover for the company is 0.75for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.40.
Conclusion
To wrap up, the performance of China SXT Pharmaceuticals Inc (SXTC) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
